# A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

Study · id `cardio:ct-nct04959305` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04959305](<https://clinicaltrials.gov/study/NCT04959305>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04959305

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

## Technical summary

Registry record NCT04959305. Randomized; double masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 245 participants (enrolled count; ClinicalTrials.gov record NCT04959305, source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)
- Started: 2021-04-22 (actual) (ClinicalTrials.gov record NCT04959305, source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)
- Primary completion: 2022-02-28 (actual) (ClinicalTrials.gov record NCT04959305, source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)
- Completion: 2022-02-28 (actual) (ClinicalTrials.gov record NCT04959305, source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04959305, source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04959305-2022-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
- Acronym: HM\_APOLLO
- Condition: Hypertension
- Intervention (Drug): HCP1803-3
- Intervention (Drug): RLD2003
- Intervention (Drug): RLD2004
- Intervention (Drug): RLD2005
- Intervention (Drug): HPP2003-3
- Intervention (Drug): HPP2005
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension (`cardio:pubmed-37095689`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 636470e181d82655c5ad1f8aa0ae90f6ee4fa1fd46ec56582539d13e2764a6c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
